Hormone combo could boost diabetes control in menopause
NCT ID NCT06715514
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether adding menopausal hormone therapy to a GLP-1 drug (semaglutide) improves blood sugar control in early postmenopausal women who have or are at risk for type 2 diabetes. About 96 women with menopausal symptoms and a BMI of 27 or higher will be enrolled. The main goal is to see if the combination works better than the GLP-1 drug alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Semaglutide (Wegovy) and menopausal hormone therapy (estradiol and micronized progesterone)
What this could lead to
If it works, this could point toward a more effective treatment for preventing or managing type 2 diabetes in early postmenopausal women.
What could go wrong
This is a small, early-phase study with only 96 participants, so results may not apply to everyone. The combination therapy may also have side effects like nausea or hormone-related risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Bern
RECRUITINGBern, 3010, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••